Potential for Nose-to-Brain Delivery of Drugs

Nanoparticles in the Lung: Environmental Exposure and Drug Delivery

Volumn , Issue , 2014, Pages 295-321

  Illum, Lisbeth ^a  

^a IDentity   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85137852777     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b17943-23     Document Type: Chapter

References (109)

1. Abdelbary G. A. and Tadros M. I., 2013. Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed micellar carriers: In vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies. Int. J. Pharm. 452: 300-310.
2. Al-Ghananeem A. M., Saeed H., Florence R., Yokel R. A. and Malkawi A. H., 2010. Intranasal drug delivery of didanosine loaded chitosan nanoparticles for brain targeting; An attractive route against infections caused by aids viruses. J. Drug Target. 18: 381-388.
3. Almeida A. J., Alpar H. O. and Brown M. R. W., 1993. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and guinea pigs. J. Pharm. Pharmacol. 45: 198-203.
4. Amidi M., Romeijn S. G., Borchard G., Junginger H. E., Hennink W. E. and Jiskoot W., 2006. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J. Control. Rel. 111: 107-116.
5. Behrens I., Vila Pena A. I., Alonso M. J. and Kissel T., 2002. Comparative uptake studies of bioadhesive nanoparticles in human intestinal cell lines and rats: The effect of mucus on particle adsorption and transport. Pharm. Res. 19: 1185-1193.
6. Betbeder D., Sperandio S., Latapie J.-P., de Nadai J., Etienne A., Zajac J.-M. and Frances B., 2000. BiovectorTM nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm. Res. 17: 743-748.
7. Bodian D. and Howe H. A., 1941. The rate of progression of poliomyelitis virus in nerves. Bull. Johns Hopkins Hosp. 69: 79-85.
8. Born J., Lange T., Kern W., McGregor G. P., Bickel U. and Fehm H. L., 2002. Sniffing neuropeptides: A transnasal approach to the human brain. Nat. Neurosci. 5: 514-516.
9. Brooking J., Davis S. S. and Illum L., 2001. Transport of nanoparticles across the rat nasal mucosa. J. Drug Target. 9: 267-279.
10. Cauna N., Hinderer K. H. and Wentges R. T., 1969. Sensory receptor organs of the human nasal respiratory mucosa. Am. J. Anat. 124: 187-209.
11. Charlton S. T., Davis S. S. and Illum L., 2007. Nasal administration of an angiotension antagonist in the rat model: Effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems. Int. J. Pharm. 338: 94-103.
12. Chen J., Zhang C., Liu Q., Shao X., Feng C., Shen Y., Zhang Q. and Jiang X., 2012. Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: In vivo and in vitro evaluations. J. Drug Target. 20: 174-184.
13. Chou K. J. and Donovan M. D., 1998. Distribution of antihistamine into the CSF following intranasal delivery. Biopharm. Drug Dispos. 18: 335-346.
14. Chow H. H. S., Chen Z. and Matsuura G. T., 1999. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci. 88: 754-758.
15. Costantino H. R., Illum L., Brandt G., Johnson P. and Quay S. C., 2007. Intranasal delivery: Physiochemical and therapeutic aspects. Int. J. Pharm. 337: 1-24.
16. Czerniawska A., 1970. Experimental investigations on the penetration of 198Au from nasal mucous membrane into cerebrospinal fluid. Acta Otolaryngol. 70: 58-61.
17. Dahlin M., 2000. Nasal administration of compounds active in the central nervous system. Dissertation, Uppsala University, Uppsala, Sweden.
18. De Lorenzo A., 1960. Electron microscopy of the olfactory and gustatory pathways. Ann. Otol. Rhinol. Laryngol. 68: 410-420.
19. Des Rieux A., Ragnarsson E. G. E., Gullberg E., Preat V., Schneider Y.-J. and Artursson P., 2005. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25: 455-465.
20. Dhuria S. V., Hanson L. R., Frey W. H. 2nd, 2009. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J. Pharm. Sci. 98(7): 2501-2515.
21. Donovan M. D. and Huang Y., 1998. Large molecule and particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv. Drug Deliv. Rev. 29: 147-155.
22. Edeling M. A., Smith C. and Owen D., 2006. Life of a clathrin coat: Insights from clathrin and AP structures. Nat. Rev. Mol. Cell. Biol. 7: 32-44.
23. Elder A., Gelein R., Silva V., Feikert T., Opanashuk L., Carter J., Potter R., Maynard A., Ito Y., Finkelstein J. and Oberdörster G., 2006. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ. Health Perspect. 114: 1172-1178.
24. Faber W. M., 1937. The nasal mucosa and the subarachnoid space. Am. J. Anat. 62: 121-148.
25. Fazil M., Md, S., Haque S., Kumar M., Baboota S., Sahni J. K. and Ali J., 2012. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 47: 6-15.
26. Feikert T., Mercer P., Corson N., Gelein R., Opanashuk L. and Elder A., 2004. Inhaled solid ultrafine particles (UFP) are efficiently translocated via neuronal naso-olfactory pathways. Toxicologist 78 (Suppl 1): 435-436.
27. Fliedner S., Schulz C. and Lehnert H., 2006. Brain uptake of intranasally applied radioiodinated leptin in Wistar rats. Endocrinology 147: 2088-2094.
28. Gao X., Chen J., Tao W., Zhu J., Zhang Q., Chen H. and Jiang X., 2007a. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int. J. Pharm. 340: 207-215.
29. Gao X., Tao W., Lu W., Zhang Q., Zhang Y., Jiang X. and Fu S., 2006. Lectin-conjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 27: 3482-3490.
30. Gao X., Wu B., Zhang Q., Chen J., Zhu J., Zhang W., Rong Z., Chen H. and Jiang X., 2007b. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control. Rel. 121: 156-167.
31. Garzotto D. and De Marchis S., 2010. Quantum dot distribution in the olfactory epithelium after nasal delivery. AIP Conf. Proc. 1275: 118-123.
32. Gold G. H., 1999. Controversial issues in vertebrate olfactory transduction. Ann. Rev. Phys. 61: 857-871.
33. Gopinath P. G., Gopinath G. and Kumar T. C. A., 1978. Target site of intranasally sprayed substances and their transport across the nasal mucosa: A new insight into the intranasal route of drug delivery. Curr. Ther. Res. 23: 596-607.
34. Gross E. A., Swenberg J. A., Fields S. and Popp J. A., 1982. Comparative morphometry of the nasal cavity in rats and mice. J. Anat. 135: 83-88.
35. Harkema J. R., 1990. Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants. Environ. Health Perspect. 85: 231-238.
36. Harush-Frenkel O., Rozentur E., Benita S. and Altschuler Y., 2008. Surface charge of nanoparticles determines their endocytotic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9: 435-443.
37. Haskell R. and Constantinides P. P., 2012. Perspectives in pharmaceutical nanotechnology. AAPS Newsmag. 15: 16-23.
38. Hayashi M., Hirasawa T., Muraoka T., Shiga M. and Awaza S., 1985. Comparison of water influx and sieving coefficient in rat jejunal, rectal and nasal absorption of antipyrine. Chem. Pharm. Bull. 33: 2149-2152.
39. Hilger P. A., 1989. Applied anatomy and physiology of the nose. In: Otolaryngology. A Textbook of Ear, Nose and Throat Diseases. W.B. Saunders, Philadelphia, PA, pp. 177-195.
40. Hillary A. M. and Florence A. T., 1996. The effect of absorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60 nm polystyrene particles after oral administration in the rats. Int. J. Pharm. 132: 123-130.
41. Howe H. A. and Bodian D., 1940. Portals of entry of poliomyelitis virus in the chimpanzee. Proc. Soc. Exp. Biol. Med. 43: 718-721.
42. Huang Y. and Donovan M. D., 1996. Microsphere transport pathways in the rabbit nasal mucosa. Int. J. Pharm. Adv. 1: 298-309.
43. Hunter D. D., Castranova V., Stanley C. and Dey R. D., 1998. Effects of silica exposure on substance P immunoreactivity and preprotachykinin mRNA expression in trigeminal sensory neurons in Fischer 344 rats. J. Toxicol. Environ. Health A 53: 593-605.
44. Illum L., 2000. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11: 1-18.
45. Illum L., 2004. Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56: 3-17.
46. Illum L., 2007. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J. Pharm. Sci. 96: 473-483.
47. Itaya S. K., 1987. Anterograde transsynaptic transport of WGA-HRP in rat olfactory pathways. Brain Res. 409: 205-214.
48. Jackson R. T., Tigges J and Arnold W, 1979. Subarachnoid space of CNS, nasal mucosa and lymphatic system. Arch. Otolaryngol. 105: 180-184.
49. Jafek B. W., 1997. Olfactory mucosal biopsy and related histology. In: Seiden A. M. (ed.) Taste and Smell Disorders. Thieme, New York, pp. 107-127.
50. Jain R., Nabar S., Dandekar P. and Patravale V., 2010. Micellar nanocarriers: Potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm. Res. 27: 655-664.
51. Johnson N. J., Hanson L. R. and Frey II, W. H., 2010. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol. Pharm. 7: 884-893.
52. Jones A. T., 2008. Gateways and tools for drug delivery: Endocytic pathways and the cellular dynamics of cell penetrating peptides. Int. J. Pharm. 354: 34-38.
53. Joshi A. S., Patel H. S., Belgamwar V. S., Agrawal A. and Tekade A. R., 2012. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: Development, optimization and evaluation. J. Mater. Sci. Mater. Med. 23: 2163-2175.
54. Keyhani K., Scherer P. W. and Mozell M. M., 1997. A numerical model of nasal odorant transport for the analysis of human olfaction. J. Theor. Biol. 186: 279-301.
55. Köping-Höggård M., Sánchez A. and Alonso M. J., 2005. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev. Vaccines 4: 185-196.
56. Kristensson K. and Olsson Y., 1971. Uptake of exogenous proteins in mouse olfactory cells. Acta Neuropathol. 19: 145-154.
57. Kumar M., Misra A., Babbar A. K., Mishra A. K., Mishra P. and Pathak K., 2008a. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 358: 285-291.
58. Kumar M., Misra A., Mishra A. K., Mishra P. and Pathak K., 2008b. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J. Drug Target. 16: 806-814.
59. Kumar M., Pandey R. S., Patra K. C., Jain S. K., Soni M. L., Dangi J. S. and Madan J., 2013. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery. Int. J. Biol. Macromol. 61: 189-195.
60. Liu Q., Shen Y., Chen J., Gao X., Feng C., Wang L., Zhang Q. and Jiang X., 2012. Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles. Pharm. Res. 29: 546-558.
61. Liu Z., Jiang M., Kang T., Miao D., Gu G., Song Q., Yao L., Hu Q., Tu Y., Pang Z., Chen H., Jiang X., Gao X. and Chen J., 2013. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 34: 3870-3881.
62. Lochhead J. J. and Thorne R. G., 2012. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 64: 614-628.
63. Lucchini R. G., Dorman D. C., Elder A. and Veronesi B., 2012. Neurological impacts from inhalation of pollutants and the nose-brain connection. Neurotoxicology 33: 838-841.
64. Ma Z. and Lim L.-Y., 2003. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: A comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res. 20: 1812-1819.
65. Madara J. L., 2000. Modulation of tight junctional permeability. Adv. Drug Deliv. Rev. 41: 251-253.
66. Md S., Khan R. A., Mustafa G., Chuttani K., Baboota S., Sahni J. K. and Ali J., 2013. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur. J. Pharm. Sci. 48: 393-405.
67. Merkus P., 2003. Transport of non-peptide drugs from the nose to the CSF. In: Proceedings from Nasal Drug Delivery Meeting, Management Forum, London, 24-25th March.
68. Merkus P., Guchelaar H.-J., Bosch A. and Merkus F. W. H. M., 2003. Direct access to human brain after intranasal administration? Neurology 60: 1669-1671.
69. Mistry A., Stolnik S. and Illum L., 2009a. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 379: 146-157.
70. Mistry A., Zoffmann Glud S., Kjems J., Randel J., Howard K. A., Stolnik S. and Illum L., 2009b. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J. Drug Target. 17: 543-552.
71. Musumeci T., Pellitteri R., Spatuzza M. and Puglisi G., 2014. Nose-to-brain delivery: Evaluation of polymeric nanoparticles on olfactory ensheathing cells uptake. J. Pharm. Sci. 103: 628-635. doi:101002/jps.23836 (Epub ahead of print).
72. Mygind N., 1978. Nasal Allergy. Blackwell Science, Oxford, UK.
73. Mygind N. and Dahl R., 1998. Anatomy, physiology and function of the nasal cavities in health and disease. Adv. Drug Deliv. Rev. 29: 3-12.
74. Oberdörster G., Sharp Z., Atudorei V., Elder A., Gelein R., Kreyling W. and Cox C., 2004. Translocation of inhaled ultrafine particles to the brain. Inhal. Toxicol. 16: 437-445.
75. Patel D., Naik S. and Misra A., 2012. Improved transnasal transport and brain uptake of tizanidine HCl-loaded thiolated chitosan nanoparticles for alleviation of pain. J. Pharm. Sci. 101: 690-706.
76. Patel S., Chavhan S., Soni H., Babbar A. K., Mathur R., Mishra A. K. and Sawant K., 2011. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J. Drug Target. 19: 468-474.
77. Perl D. P. and Good P. F., 1987. The association of aluminum Alzheimer’s disease, and neurofibrillary tangles. J. Neural Transm. Suppl. 24: 205-211.
78. Rejman J., Oberle V., Zuhorn I. S. and Hoekstra D., 2004. Size dependent internalisation of particles via the pathway of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377: 159-169.
79. Rothermel M., Ng B. S. W., Grabska-Barwinska A., Hatt H. and Jancke D., 2011. Nasal chemosensory-stimulation evoked activity patters in the rat trigeminal ganglion visualised by in vivo voltage-sensitive dye imaging. PLoS One 6:e26158. doi:10.1371/journal.pone.0026158.
80. Ruan Y., Yao L., Zhang B., Zhang S. and Guo J., 2011. Antinoceptive properties of nasal delivery of neurotoxin-loaded nanoparticles coated with polysorbate 80. Peptides 32: 1526-1529.
81. Sadeghi A. M. M., Dorkoosh F. A., Avadi M. R., Weinhold M., Bayat A., Delie F., Gurny R., Larijani B., Rafiee-Tehrani M. and Junginger H. E., 2008. Permeation enhancer effect of chitosan and chitosan derivatives: Comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 70: 270-278.
82. Sakane T., Akizuki M., Yoshida M., Yamashita S., Nadai T., Hashida M. and Sezaki H., 1991. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J. Pharm. Pharmacol. 43(6): 449-451.
83. Schiöth H. B., Craft S., Brooks S. J., Frey II, W. H. and Benedict C., 2012. Brain insulin signalling and Alzheimer’s disease: Current evidence and future directions. Mol. Neurobiol. 46: 4-10.
84. Seju U., Kumar A. and Sawant K. K., 2011. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater. 7: 4169-4176.
85. Semmler M., Seitz J., Erbe F., Mayer P., Heyder J., Oberdorster G. and Kreyling W. G., 2004. Long-term clearance kinetics of inhaled ultrafine insoluble iridium particles from the rat lung, including transient translocation into secondary organs. Inhal. Toxicol. 16: 453-459.
86. Shen Y., Chen J., Liu Q., Feng C., Gao X., Wang L., Zhang Q. and Jiang X., 2011. Effect of wheat germ agglutinin density on cellular uptake and toxicity of wheat germ agglutinin conjugated PEG-PLA nanoparticles in Calu-3 cells. Int. J. Pharm. 413: 184-193.
87. Shipley M. T., 1985. Transport of molecules from nose to brain: Transneural anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res. Bull. 15: 129-142.
88. Shorten P. R., McMahon C. D. and Soboleva T. K., 2007. Insulin transport within skeletal muscle transverse tubule networks. Biophys. J. 93: 3001-3007.
89. Silver W. L., 1992. Neural and pharmacological basis for nasal irritation. Ann. N. Y. Acad. Sci. 641: 152-163.
90. Slütter B., Bal S., Keijzer C., Mallants R., Hagenaars N., Que I., Kaijzel E., van Eden W., Augustijns P., Löwik C., Bouwstra J., Broere F. and Jiskoot W., 2010. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 28: 6282-6291.
91. Stevenson B. R., Anderson J. M. and Bullivant S., 1988. The epithelial tight junction: Structure, function and preliminary biochemical characterisation. Mol. Cell Biochem. 83: 129-145.
92. Thorne R. G., Emory C. R., Ala T. A. and Frey II, W. H., 1995. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 692: 278-282.
93. Thorne R. G. and Frey W. H., 2001. Delivery of neurotropic factors to the central nervous system. Clin. Pharmacokinet. 40: 907-946.
94. Thorne R. G., Hanson L. R., Ross T. M., Tung D. and Frey II, W. H., 2008. Delivery of interferon-b to the monkey nervous system following intranasal administration. Neuroscience 152: 785-797.
95. Thorne R. G., Pronk G. J., Padmanabhan V. and Frey W. H., 2004. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127: 481-496.
96. Vila A., Sanchez A., James K., Behrens I., Kissel T., Jato J. L. V. and Alonso M. J., 2004. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57: 123-131.
97. Wang B., Feng W. Y., Wang M., Shi J. W., Zhang F., Ouyang H., Zhao Y. L., Chai Z. F., Huang Y. Y., Wang H. F. and Wang J., 2007. Transport of intranasally instilled fine Fe23 particles into the brain: Micro-distribution, chemical states and histopathological observation. Biol. Trace Elem. Res. 118: 233-243.
98. Wang J., Liu Y., Jiao F., Lao F., Li W., Gu Y., Li Y., Ge C., Zhou G., Li B., Zhao Y., Chai Z. and Chen C., 2008a. Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO(2) nanoparticles. Toxicology 254: 82-90.
99. Wang X., Chi N. and Tang X., 2008. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur. J. Pharm. Biopharm. 70: 735-740.
100. Wang X., He H., Leng W. and Tang X., 2006. Evaluation of brain targeting for the nasal delivery of estradiol by the microdialysis method. Int. J. Pharm. 317: 40-46.
101. Wang Y., Aun R. and Tse F. L. S., 1998. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm. Drug Dispos. 19: 571-575.
102. Wang Y.-Y., Lai S. K., Suk J. S., Pace A., Cone R. and Hanes J., 2008b. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that ‘slip’ through the human mucus barrier. Angew. Chem. Int. Ed. Engl. 47: 9726-9729.
103. Wen Z., Yan Z., He R., Pang Z., Guo L., Qian Y., Jiang X. and Fang L., 2011a. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration. Drug Deliv. 18: 556-561.
104. Wen Z., Yan Z., Hu K., Pang Z., Cheng X., Guo L., Zhang Q., Jiang X., Fang L. and Lai R., 2011b. Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J. Control. Rel. 151: 131-138.
105. Xia H., Gao X., Gu G., Liu Z., Zeng N., Hu Q., Song Q., Yao L., Pang Z., Jiang X., Chen J. and Chen H., 2011. Low molecular weight protamine-functionalised nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 32: 9888-9898.
106. Yamamoto Y., Kondo A., Atoji Y., Tsubone H. and Suzuki Y., 1998. Morphology of intraepithelial corpuscular nerve endings in the nasal respiratory mucosa of the dog. J. Anat. 193: 581-586.
107. Zhang Q., Jiang X., Jiang W., Lu W., Su L. and Shi Z., 2004. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int. J. Pharm. 275: 85-96.
108. Zhang Q.-Z., Zha L.-S., Zhang Y., Jiang W.-M., Lu W., Shi Z.-Q., Jiang X.-G. and Fu S.-K., 2006. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J. Drug Target. 14: 281-290.
109. Zhao Y. Z., Li X., Lu C. T., Lin M., Chen L. J., Xiang Q., Zhang M., Jin R. R., Jiang X., Shen X. T., Li X. K. and Cai J., 2014. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine. 10(4): 755-764.